Exact Sciences Appoints Leslie Trigg to Board of Directors, Replacing Kathleen Sebelius

Exact Sciences Corporation announced that Leslie Trigg has been appointed to its Board of Directors as a Class II member, with her term extending through the company’s 2026 annual meeting of shareholders. Trigg, the current CEO and Chair of Outset Medical, brings over 25 years of experience in the healthcare and medical device sectors, including leadership roles at Warburg Pincus, Lutonix, and FoxHollow Technologies. She replaces Kathleen Sebelius, who resigned on April 29, 2025, for retirement. The company expressed appreciation for Sebelius’ years of service. Trigg will receive a stock award valued at $375,000 as part of the company's Non-Employee Director Compensation Policy.

Exact Sciences reported fourth-quarter 2024 revenue of $713 million, reflecting a 10% year-over-year increase, and full-year revenue of $2.76 billion, also up 10%. Screening revenue reached $553 million in the quarter, growing 14%, while Precision Oncology revenue was $161 million, up 0.4%. Gross margin was 69%, and adjusted gross margin was 72%. The company posted an $865 million net loss due to an $838 million impairment charge related to the Thrive acquisition. Adjusted EBITDA rose to $75 million, with a margin of 11%.

Exact Sciences plans to launch three new cancer screening tests in 2025: Cologuard Plus, an improved colorectal cancer screening test; Oncodetect, a molecular residual disease test; and Cancerguard, a multi-cancer early detection test. The company secured favorable Medicare pricing for Cologuard Plus, which is expected to launch in Q2 2025. Data from the ASCEND 2 study supported the effectiveness of Cancerguard, and Exact Sciences aims to introduce it in the second half of 2025. Additionally, Oncodetect showed strong performance in detecting residual colorectal cancer, with commercial launch planned for Q2 2025.